ASH 2022 | Molecular characterization of patients in AGILE: azacitidine + ivosidenib or placebo in IDH1m AML

Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, comments on the results and molecular characterization of patients from the AGILE study (NCT03173248), which investigated ivosidenib plus azacitidine versus placebo plus azacitidine in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML). Dr de Botton highlights the frequency and clearance of mutations observed in patients, including IDH1, NRAS, DNMT3A, TET2, and ASXL1, and also comments on the emergence of new mutations. Overall, the study demonstrated that ivosidenib plus azacitidine leads to deep and durable responses, showed significant clinical benefit compared to placebo, and achieved clearance of all baseline mutations in this difficult-to-treat population. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.